Edition:
United States

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

11.21USD
18 Jun 2018
Change (% chg)

$-0.09 (-0.80%)
Prev Close
$11.30
Open
$11.25
Day's High
$11.35
Day's Low
$10.57
Volume
71,143
Avg. Vol
71,155
52-wk High
$20.73
52-wk Low
$5.42

Chart for

About

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which... (more)

Overall

Beta: --
Market Cap(Mil.): $153.24
Shares Outstanding(Mil.): 13.56
Dividend: --
Yield (%): --

Financials

  ZYNE.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -2.79 -- --
ROI: -57.57 -5.87 13.17
ROE: -57.86 -7.71 15.15

BRIEF-Zynerba Pharmaceuticals Reports Q1 Loss Of $0.91 Per Share

* ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

May 08 2018

BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study

* ZYNERBA PHARMACEUTICALS SAYS ZYN002 WAS SHOWN TO BE WELL TOLERATED THROUGH 12 MONTHS OF TREATMENT IN STAR 2

Apr 25 2018

BRIEF-Zynerba Pharmaceuticals Appoints John P. Butler To Board Of Directors

* ZYNERBA PHARMACEUTICALS APPOINTS JOHN P. BUTLER TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 16 2018

BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)

* ZYNERBA PHARMACEUTICALS INITIATES OPEN-LABEL PHASE 2 TRIAL OF ZYN002 IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE)

Apr 10 2018

BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60

* ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Mar 12 2018

BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing

* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING

Mar 05 2018

BRIEF-Zynerba Pharmaceuticals Inc ‍Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year End ​

* ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE

Jan 03 2018

Earnings vs. Estimates